Previous studies identified circulating CD14⁺HLA‐DR^lo/− monocytic cells as an immune suppressive subset in solid malignancies, such as prostate, renal cell carcinoma, and pancreatic cancer. Such monocytic cells have been implicated not only in tumour progression but also as a potential barrier for immunotherapy. This study examined the relationship between the frequency of circulating monocytic cells and epithelial ovarian cancer (EOC) progression pre‐ and post‐frontline chemotherapy, defined by disease stage, which is a leading prognostic factor for this malignancy.

中文翻译：

---

循环 CD14+HLA-DRlo/- 单核细胞作为上皮性卵巢癌进展的生物标志物

先前的研究将循环 CD14 ⁺ HLA-DR ^lo/-单核细胞确定为实体恶性肿瘤（如前列腺癌、肾细胞癌和胰腺癌）中的免疫抑制亚群。这种单核细胞不仅与肿瘤进展有关，而且还作为免疫治疗的潜在障碍。本研究检查了循环单核细胞的频率与上皮性卵巢癌 (EOC) 进展前后一线化疗之间的关系，由疾病分期定义，这是该恶性肿瘤的主要预后因素。